Zacks: Analysts Anticipate NeuBase Therapeutics, Inc. (NASDAQ:NBSE) to Announce -$0.27 Earnings Per Share

Analysts expect NeuBase Therapeutics, Inc. (NASDAQ:NBSE) to report earnings of ($0.27) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for NeuBase Therapeutics’ earnings. The highest EPS estimate is ($0.26) and the lowest is ($0.27). NeuBase Therapeutics posted earnings per share of ($0.20) in the same quarter last year, which indicates a negative year-over-year growth rate of 35%. The firm is scheduled to report its next earnings results on Wednesday, December 22nd.

According to Zacks, analysts expect that NeuBase Therapeutics will report full-year earnings of ($0.95) per share for the current fiscal year, with EPS estimates ranging from ($0.99) to ($0.88). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.03) per share, with EPS estimates ranging from ($1.34) to ($0.87). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that cover NeuBase Therapeutics.

NeuBase Therapeutics (NASDAQ:NBSE) last released its earnings results on Thursday, August 12th. The company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.05).

A number of research analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of NeuBase Therapeutics in a research note on Monday, September 13th. Zacks Investment Research raised shares of NeuBase Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, September 29th.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC acquired a new stake in shares of NeuBase Therapeutics during the 2nd quarter worth approximately $33,000. Heritage Wealth Advisors increased its holdings in NeuBase Therapeutics by 80.0% in the 2nd quarter. Heritage Wealth Advisors now owns 9,000 shares of the company’s stock valued at $63,000 after purchasing an additional 4,000 shares during the last quarter. Walleye Capital LLC acquired a new stake in NeuBase Therapeutics in the 2nd quarter valued at approximately $82,000. Royal Bank of Canada increased its holdings in NeuBase Therapeutics by 121.1% in the 1st quarter. Royal Bank of Canada now owns 11,244 shares of the company’s stock valued at $83,000 after purchasing an additional 6,158 shares during the last quarter. Finally, Trexquant Investment LP acquired a new stake in NeuBase Therapeutics in the 2nd quarter valued at approximately $92,000. Institutional investors and hedge funds own 31.85% of the company’s stock.

NBSE opened at $3.89 on Monday. The company’s 50 day simple moving average is $3.72 and its two-hundred day simple moving average is $4.67. NeuBase Therapeutics has a 1-year low of $3.26 and a 1-year high of $12.89. The firm has a market capitalization of $127.27 million, a price-to-earnings ratio of -4.27 and a beta of -0.01.

NeuBase Therapeutics Company Profile

NeuBase Therapeutics, Inc is a biotechnology company. It engages in the development of drugs for patients with genetic neurological disorder. The firms pipelines include Huntington’s Disease, NT0100 Program – PATrOL Enabled gamma-PNA for Huntington’s Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy.

Recommended Story: Most Volatile Stocks

Get a free copy of the Zacks research report on NeuBase Therapeutics (NBSE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NeuBase Therapeutics (NASDAQ:NBSE)

Receive News & Ratings for NeuBase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuBase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.